As of Nov 19, 2026, 2 of 2 active firms rate DERM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DERM EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $0.01 – $0.01 · 1 analysts · -113% YoY
Next period, 1 analysts expect Journey Medical Corp to earn $0.01 a share (range $0.01 – $0.01), versus $-0.08 a year earlier. Full-year consensus is $-0.07, growing to $0.41 the year after.
REVENUE · NEXT QUARTER
$21.2M
Range $19.7M – $22.8M · 1 analysts · +33% YoY
Revenue is expected to reach $21.2M (range $19.7M – $22.8M), +33.0% year-over-year. Full-year consensus is $72.7M, rising to $100.7M next year.
Top analysts covering Journey Medical Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DERM.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$15.00+304.3% to target
Overall win rate
49%
+ Follow
#2
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$13.00+250.4% to target
Overall win rate
40%
+ Follow
#3
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$13.00+250.4% to target
Overall win rate
38%
+ Follow
#4
SH
Scott Henry
Alliance Global Partners
Buy
$14.00+277.4% to target
Coverage
—
+ Follow
#5
KP
Kalpit Patel
B. Riley Securities
Buy
$12.00+223.5% to target
Coverage
—
+ Follow
DERM stock forecast FAQ
What is DERM's average 12-month price target?+
The 2 active firms with a live target average $14.00 for Journey Medical Corp over the next 12 months, ranging from a $15.00 high to a $13.00 low, as of Nov 19, 2026.
Is DERM stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DERM?+
The Street-high target is $15.00 (B. Riley Securities), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $14.00.
How many active Wall Street firms cover DERM?+
2 active firms have a recognized rating on Journey Medical Corp as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DERM?+
Among analysts who currently cover DERM, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $15.00 target.
What is Journey Medical Corp's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $0.01 – $0.01) across 1 analysts. Full-year EPS is projected at $-0.07, rising to $0.41 the following year.
How much revenue is Journey Medical Corp expected to report next quarter?+
Consensus revenue is $21.2M (range $19.7M – $22.8M). Full-year revenue is projected at $72.7M, growing to $100.7M next year.
Have analysts been upgrading or downgrading DERM lately?+
As of Nov 19, 2026, 2 of 2 active firms rate DERM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DERM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.